SV Health Investors
Venture capital firm based in London, UK
Latest SV Health Investors investments
SV Health Investors has invested in these startups.
Mestag Therapeutics
Mestag Therapeutics raises £30.1m to test FAP-targeted bispecific remodelling tumour environment. Read more
Artios
Artios lands £87.4m to advance new targeted treatments for hard-to-treat cancers. Read more
Alchemab Therapeutics
Alchemab Therapeutics secures fresh funding in a Series A extension, aiming to develop groundbreaking therapies for muscle atrophy and beyond. Read more
NRG Therapeutics
NRG Therapeutics secures £50 million to advance neurodegenerative treatments with its lead drug, NRG5051, aiming for clinical trials by 2026. Read more
Enara Bio
Enara Bio secures a game-changing $32.5 million in Series B funding, setting the stage to revolutionize cancer therapy with its innovative Dark Antigen targets. Read more
Harness Therapeutics
Cambridge-based biotech company, Harness Therapeutics, secures an impressive £4 million in additional funding to advance its lead programme in targeting Huntington's Disease, bringing their total raised to £17.6 million. Read more
Sitryx Therapeutics
Sitryx Therapeutics secures $39 million funding to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases by regulating cell metabolism, with new investor Oxford Science Enterprises joining a strong healthcare investor lineup. Read more
Investments By Sector
SV Health Investors has invested in these sectors
| Biotech | 77.8% |
| Healthtech | 22.2% |
